Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

Masaki Shiota(Kyushu University), Amina Zoubeidi(University of British Columbia)
Oncotarget
March 15, 2015
Cited by 44


Related Papers